Daniel Gaudet

34.0k total citations · 20 hit papers
418 papers, 19.0k citations indexed

About

Daniel Gaudet is a scholar working on Surgery, Cardiology and Cardiovascular Medicine and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Daniel Gaudet has authored 418 papers receiving a total of 19.0k indexed citations (citations by other indexed papers that have themselves been cited), including 206 papers in Surgery, 183 papers in Cardiology and Cardiovascular Medicine and 136 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Daniel Gaudet's work include Lipoproteins and Cardiovascular Health (171 papers), Lipid metabolism and disorders (154 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (106 papers). Daniel Gaudet is often cited by papers focused on Lipoproteins and Cardiovascular Health (171 papers), Lipid metabolism and disorders (154 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (106 papers). Daniel Gaudet collaborates with scholars based in Canada, United States and Netherlands. Daniel Gaudet's co-authors include Diane Brisson, Marie‐Claude Vohl, Thomas J. Hudson, Claude Gagné, Joel N. Hirschhorn, David Altshuler, Patrice Perron, Jean Bergeron, G Tremblay and Karine Tremblay and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Circulation.

In The Last Decade

Daniel Gaudet

399 papers receiving 18.5k citations

Hit Papers

The common PPARγ Pro12Ala polymorphism is associated with... 2000 2026 2008 2017 2000 2000 2010 2014 2012 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes
    2000 1.3k citations Daniel Gaudet et al. profile →
  2. Hypertriglyceridemic Waist
    2000 753 citations Daniel Gaudet et al. profile →
  3. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial
    2010 692 citations Frederick J. Raal, Raúl D. Santos et al. profile →
  4. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
    2014 562 citations Frederick J. Raal, Daniel Gaudet et al. profile →
  5. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study
    2012 524 citations Marina Cuchel, Robert A. Hegele et al. profile →
  6. Evinacumab for Homozygous Familial Hypercholesterolemia
    2020 470 citations Frederick J. Raal, Poulabi Banerjee et al. profile →
  7. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial
    2012 463 citations Daniel Gaudet, Robert Pordy et al. profile →
  8. Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome
    2019 416 citations Joseph L. Witztum, Daniel Gaudet et al. profile →
  9. Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
    2015 409 citations Daniel Gaudet, Veronica J. Alexander et al. profile →
  10. Targeting APOC3 in the Familial Chylomicronemia Syndrome
    2014 381 citations Daniel Gaudet, Diane Brisson et al. profile →
  11. Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease
    2022 312 citations J. Antonio G. López, Seth J. Baum et al. profile →
  12. Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance
    2019 301 citations Daniel Gaudet et al. profile →
  13. Evinacumab in Patients with Refractory Hypercholesterolemia
    2020 215 citations Seth J. Baum, Robert Pordy et al. profile →
  14. Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk
    2021 146 citations Ewa Karwatowska‐Prokopczuk, Christie M. Ballantyne et al. European Heart Journal profile →
  15. Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia
    2024 103 citations Daniel Gaudet, Robert A. Hegele et al. profile →
  16. Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia
    2024 103 citations Christie M. Ballantyne, Szilárd Vasas et al. profile →
  17. Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk
    2024 102 citations Veronica J. Alexander, Daniel Gaudet et al. profile →
  18. Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia
    2024 90 citations Daniel Gaudet, Gerald F. Watts et al. profile →
  19. Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk
    2024 66 citations Gerald F. Watts, Robert S. Rosenson et al. profile →
  20. Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3): a double-blind, randomised, placebo-controlled, phase 2 trial
    2025 16 citations Robert S. Rosenson, Daniel Gaudet et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniel Gaudet Canada 66 8.7k 5.9k 5.6k 5.2k 2.9k 418 19.0k
Robert A. Hegele Canada 81 10.3k 1.2× 7.8k 1.3× 8.1k 1.4× 7.7k 1.5× 3.4k 1.2× 731 26.8k
Florian Kronenberg Austria 73 6.6k 0.8× 3.6k 0.6× 3.4k 0.6× 4.7k 0.9× 2.0k 0.7× 380 20.4k
Anne Tybjærg‐Hansen Denmark 81 11.0k 1.3× 9.3k 1.6× 7.4k 1.3× 5.1k 1.0× 4.0k 1.4× 345 28.3k
Sergio Fazio United States 74 6.4k 0.7× 6.6k 1.1× 4.3k 0.8× 6.1k 1.2× 2.0k 0.7× 315 20.2k
Eric J.G. Sijbrands Netherlands 59 5.1k 0.6× 3.1k 0.5× 3.1k 0.6× 2.0k 0.4× 1.5k 0.5× 276 12.5k
Ruth McPherson Canada 52 3.8k 0.4× 2.1k 0.4× 1.8k 0.3× 3.8k 0.7× 1.5k 0.5× 197 11.4k
Raúl D. Santos Brazil 48 5.9k 0.7× 3.6k 0.6× 3.5k 0.6× 1.4k 0.3× 1.6k 0.5× 375 12.8k
Sekar Kathiresan United States 53 3.2k 0.4× 2.3k 0.4× 3.2k 0.6× 3.2k 0.6× 1.3k 0.5× 106 13.8k
G. A. Hitman United Kingdom 57 5.1k 0.6× 4.2k 0.7× 1.5k 0.3× 3.4k 0.7× 677 0.2× 245 13.0k
François Mach Switzerland 73 5.7k 0.7× 1.9k 0.3× 4.3k 0.8× 4.4k 0.8× 2.5k 0.8× 420 19.3k

Countries citing papers authored by Daniel Gaudet

Since Specialization
Citations

This map shows the geographic impact of Daniel Gaudet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Gaudet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Gaudet more than expected).

Fields of papers citing papers by Daniel Gaudet

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Gaudet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Gaudet. The network helps show where Daniel Gaudet may publish in the future.

Co-authorship network of co-authors of Daniel Gaudet

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Gaudet. A scholar is included among the top collaborators of Daniel Gaudet based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Gaudet. Daniel Gaudet is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Banerjee, Poulabi, et al.. (2025). Treatment With Evinacumab Links a New Pathogenic Variant in the LPL Gene to Persistent Chylomicronemia. Journal of the Endocrine Society. 9(4). bvaf025–bvaf025. 2 indexed citations
2.
Brown, Alan S., Philippe Moulin, Veronica J. Alexander, et al.. (2025). Brief communication: Strong concordance of the North American Familial Chylomicronemia Syndrome Score with a positive genetic diagnosis in patients from the Balance study. Journal of clinical lipidology. 19(5). 1451–1456. 1 indexed citations
3.
Saadatagah, Seyedmohammad, Mohammadreza Naderian, Vijay Nambi, et al.. (2025). Recognition and management of persistent chylomicronemia: A joint expert clinical consensus by the National Lipid Association and the American Society for Preventive Cardiology. American Journal of Preventive Cardiology. 22. 100978–100978. 2 indexed citations
4.
Bajaj, Archna, Elif A Oral, Alan S. Brown, et al.. (2025). Clinical considerations for the treatment of patients with familial chylomicronemia syndrome using a hepatic-targeted APOC3 antisense oligonucleotide. American Journal of Preventive Cardiology. 24. 101352–101352.
5.
Kessler, Asia Sikora, T. Michelle Brown, Emily Bratlee‐Whitaker, et al.. (2025). Patient experience with familial chylomicronemia syndrome before and after olezarsen treatment: Qualitative interviews with clinical trial participants. Journal of clinical lipidology. 19(5). 1243–1255. 1 indexed citations
6.
Raal, Frederick J., Robert A. Hegele, Andrea Ruzza, et al.. (2024). Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies. Arteriosclerosis Thrombosis and Vascular Biology. 44(5). 1156–1164. 9 indexed citations
7.
Abifadel, Marianne, Alberico L. Catapano, Marina Cuchel, et al.. (2024). SMASH: An initiative for equitable access to precision medicine for rare or severe lipid disorders. 3(3). 81–86.
8.
Vasas, Szilárd, Masoud Azizad, Peter Clifton, et al.. (2024). †Plozasiran (ARO-APOC3), an Investigational RNAi, Demonstrates Robust and Durable TG Reductions in Patients with Mixed Dyslipidemia, MUIR Final Results. Journal of clinical lipidology. 18(4). e560–e560.
9.
Khoury, Étienne, et al.. (2024). Emerging therapies for refractory hypercholesterolemia: a narrative review. Future Cardiology. 20(5-6). 317–334.
10.
11.
Ruel, Isabelle L., Patrick Couture, Jean Bergeron, et al.. (2023). Familial hypercholesterolemia in Canada: Investigating management patterns and clinical outcomes from the FH Canada registry. Atherosclerosis. 379. S31–S31. 1 indexed citations
12.
Pordy, Robert, et al.. (2023). CLINICAL TRIAL WITH THE ANGPTL3 MONOCLONAL ANTIBODY EVINACUMAB IDENTIFIES A NEW RARE CHYLOMICRONEMIA CAUSING VARIANT IN THE LPL GENE. Canadian Journal of Cardiology. 39(10). S183–S183. 1 indexed citations
13.
Sliz, Eeva, Jean Shin, Michael V. Holmes, et al.. (2022). Visceral adiposity is associated with metabolic profiles predictive of type 2 diabetes and myocardial infarction. SHILAP Revista de lepidopterología. 2(1). 81–81. 22 indexed citations
14.
Gaudet, Daniel, Ewa Karwatowska‐Prokopczuk, Seth J. Baum, et al.. (2020). Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia. European Heart Journal. 41(40). 3936–3945. 196 indexed citations
15.
Sliz, Eeva, Jean Shin, Catriona Syme, et al.. (2020). A variant near DHCR24 associates with microstructural properties of white matter and peripheral lipid metabolism in adolescents. Molecular Psychiatry. 26(8). 3795–3805. 10 indexed citations
16.
Yadav, Narendra Singh, et al.. (2020). Transient expression of the β-glucuronidase gene in Cannabis sativa varieties. Plant Signaling & Behavior. 15(8). 1780037–1780037. 22 indexed citations
17.
Syme, Catriona, Jean Shin, Louis Richer, et al.. (2019). Sex Differences in Blood Pressure Hemodynamics in Middle-Aged Adults With Overweight and Obesity. Hypertension. 74(2). 407–412. 12 indexed citations
18.
Banerjee, Poulabi, Kuo‐Chen Chan, Asier Benito‐Vicente, et al.. (2019). Functional Analysis of LDLR (Low-Density Lipoprotein Receptor) Variants in Patient Lymphocytes to Assess the Effect of Evinacumab in Homozygous Familial Hypercholesterolemia Patients With a Spectrum of LDLR Activity. Arteriosclerosis Thrombosis and Vascular Biology. 39(11). 2248–2260. 64 indexed citations
19.
Syme, Catriona, Jean Shin, Michał Abrahamowicz, et al.. (2018). Visceral fat-related systemic inflammation and the adolescent brain: a mediating role of circulating glycerophosphocholines. International Journal of Obesity. 43(6). 1223–1230. 21 indexed citations
20.
Tremblay, Monique, Diane Brisson, & Daniel Gaudet. (2016). Association between a polymorphic poly-T repeat sequence in the promoter of the somatostatin gene and hypertension. Hypertension Research. 39(6). 467–474. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Robert A. Hegele Breakdown of academic impact, for papers by Florian Kronenberg Breakdown of academic impact, for papers by Anne Tybjærg‐Hansen Breakdown of academic impact, for papers by Sergio Fazio Breakdown of academic impact, for papers by Eric J.G. Sijbrands Breakdown of academic impact, for papers by Ruth McPherson Breakdown of academic impact, for papers by Raúl D. Santos Breakdown of academic impact, for papers by Sekar Kathiresan Breakdown of academic impact, for papers by G. A. Hitman Breakdown of academic impact, for papers by François Mach
Rankless by CCL
2026